High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

BACKGROUND: Src homology region 2 domain‐containing phosphatase 2 (SHP2) is a novel target for Kirsten rat sarcoma oncogene (KRAS) mutant cancer. We retrospectively studied the significance of SHP2 in KRAS mutant non‐small cell lung cancer (NSCLC) treated with immunotherapy and its relationship with...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Hui‐Bo, Chen, Yu, Xie, Zhi, Jiang, Jie, Zhong, Yu‐Min, Guo, Wei‐Bang, Yan, Wen‐Qing, Lv, Zhi‐Yi, Lu, Dan‐Xia, Liang, Hong‐Ling, Xu, Fang‐Ping, Yang, Jin‐Ji, Yang, Xue‐Ning, Zhou, Qing, Zhang, Dong‐Kun, Zhang, Zhou, Chuai, Shao‐Kun, Zhang, Heng‐Hui, Wu, Yi‐Long, Zhang, Xu‐Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487814/
https://www.ncbi.nlm.nih.gov/pubmed/34490728
http://dx.doi.org/10.1111/1759-7714.14137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487814/
https://www.ncbi.nlm.nih.gov/pubmed/34490728
http://dx.doi.org/10.1111/1759-7714.14137

Ejemplares similares